Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice

Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Pharmacol Res Perspect
Hoofdauteurs: Tao, Linfen, Guo, Xiaolong, Xu, Min, Wang, Yumeng, Xie, Wenhua, Chen, Hong, Ma, Mengyao, Li, Xi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/
https://ncbi.nlm.nih.gov/pubmed/33474802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items